![\"cr\"](\"https:\/\/techma.bakertilly.es\/wp-content\/uploads\/2020\/09\/cr.jpg\" "\\"\\"")
<\/p>\n<\/p>\n
Avet Ventures launches Strengzen, its first proprietary investment vehicle<\/strong><\/span><\/p>\n Avet Ventures has launched its first own fund, Strengzen Invest, to invest temporarily in innovative companies, but not exclusively in dotcoms, but also in more traditional sectors, such as retail and FMCG.<\/span><\/p>\n Avet Ventures was established in January 2015 as a management company of closed-end investment entities and started operating, managing the portfolio of investees of the funds FonsInnocat and Highgrowth Innovation, after the closing of the firm. Highgrowth Partners.<\/a><\/span><\/span><\/p>\n Avet is now launching its own venture capital instrument. This fund, despite the firm's initial intentions, will be a small fund. The company has been set up with resources of \u20ac1.4M but already has \u20ac5M, and its final figure could be between \u20ac6M and \u20ac10M.<\/span><\/p>\n The intention, according to the company's president, is to execute between eight and ten investments with an average amount of between 250,000 euros and 300,000 euros.<\/span><\/p>\n \u00a0<\/strong><\/span><\/p>\n La Caixa and the CDTI launch<\/strong> a fund for science start-ups<\/strong><\/span><\/p>\n A month ago we already told you about this fund in one of our posts, but now we know that it has started its activity and has invested in Aelix, a company from the Catalan research centre Hivacat that works on the development of\u00a0a therapeutic AIDS vaccine<\/a>.<\/span><\/p>\n This fund will invest in early stage biotech companies. Normally these companies have difficulty finding capital in our country, as these companies need a long time to reach the market because they have to comply with regulatory steps that delay the process. Firms like Aelix spend years in research phases, tests on animals and then on human beings before they can have a definitive result that can be marketed.<\/span><\/p>\n The investments of this new fund will be between 500,000 and 2 million euros in each operation, through capital contributions, taking minority stakes in the start-ups.<\/span><\/p>\n The fund will invest in ten to twenty companies, mostly in the life sciences, per year.<\/span><\/p>\n \u00a0If you are looking for funding for your startup, contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Call + 34 946424142 or fill in the contact form.<\/span><\/p>\n Other posts that may interest you<\/span><\/strong><\/p>\n Caixa Capital Risk invests in Inbiomotion<\/a><\/span><\/p>\n Divestment of Avet Ventures in the Catalan company Nuroa<\/a><\/span><\/p>\n